Assertio (ASRT)
(Delayed Data from NSDQ)
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Zacks News
ASRT or UTHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. UTHR: Which Stock Is the Better Value Option?
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $2.21, marking a +1.38% move from the previous day.
Select Medical (SEM) Plans 3rd Hospital in Central Pennsylvania
by Zacks Equity Research
Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.
Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $2.31, moving +1.76% from the previous trading session.
ASRT vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. STVN: Which Stock Is the Better Value Option?
Why Should You Retain Cigna (CI) in Your Portfolio Now?
by Zacks Equity Research
Cigna (CI) is aided by powerful segmental performances, solid demand for its Medicare plans, divestitures and solid cash-generating abilities.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $2.15 in the latest trading session, marking a +0.94% move from the prior day.
Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?
by Zacks Equity Research
Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal
by Zacks Equity Research
Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.
Down 18.3% in 4 Weeks, Here's Why Assertio (ASRT) Looks Ripe for a Turnaround
by Zacks Equity Research
Assertio (ASRT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Assertio (ASRT) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $2.24 in the latest trading session, marking no change from the prior day.
Centene (CNC) Wins Contract to Serve Texas' Foster Population
by Zacks Equity Research
Centene's (CNC) Texas subsidiary secures a contract to continue catering to the state's foster children and youth via its Medicaid plans.
ASRT vs. STVN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. STVN: Which Stock Is the Better Value Option?
Is Most-Watched Stock Assertio Holdings, Inc. (ASRT) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $2.74 in the latest trading session, marking a +1.3% move from the prior day.
Pacira (PCRX) Up on Data From Exparel Label Expansion Study
by Zacks Equity Research
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Assertio (ASRT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%
by Zacks Equity Research
After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.
5 Cheap Healthcare Stocks in 2022
by Tracey Ryniec
Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?
AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids
by Zacks Equity Research
AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients
BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU
by Zacks Equity Research
BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.
ASRT or CORT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. CORT: Which Stock Is the Better Value Option?